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ABSTRACT
Ellipticine is a potent antineoplastic agent exhibiting multiple mechanisms of action. This anticancer agent should be considered 
a pro-drug, whose pharmacological efficiency and/or genotoxic side effects are dependent on its cytochrome P450 (CYP)- and/
or peroxidase-mediated activation to species forming covalent DNA adducts. Ellipticine can also act as an inhibitor or inducer of 
biotransformation enzymes, thereby modulating its own metabolism leading to its genotoxic and pharmacological effects. Here, 
a comparison of the toxicity of ellipticine to human breast adenocarcinoma MCF-7 cells, leukemia HL-60 and CCRF-CEM cells, neu-
roblastoma IMR-32, UKF-NB-3 and UKF-NB-4 cells and U87MG glioblastoma cells and mechanisms of its action to these cells were 
evaluated. Treatment of all cells tested with ellipticine resulted in inhibition of cell growth and proliferation. This effect was associated 
with formation of two covalent ellipticine-derived DNA adducts, identical to those formed by 13-hydroxy- and 12-hydroxyellipticine, 
the ellipticine metabolites generated by CYP and peroxidase enzymes, in MCF-7, HL-60, CCRF-CEM, UKF-NB-3, UKF-NB-4 and U87MG 
cells, but not in neuroblastoma UKF-NB-3 cells. Therefore, DNA adduct formation in most cancer cell lines tested in this comparative 
study might be the predominant cause of their sensitivity to ellipticine treatment, whereas other mechanisms of ellipticine action also 
contribute to its cytotoxicity to neuroblastoma UKF-NB-3 cells. 
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Neurospora crassa, and mammalian cells and induce 
prophage lambda in Escherichia coli (for an overview see 
Stiborová et al., 2001). 
Ellipticine has been reported to arrest cell cycle pro-
gression by regulating the expression of cyclin B1 and Cdc2 
as well as phosphorylation of Cdc2 (Kuo et al., 2005a; b) to 
induce apoptotic cell death by generation of cytotoxic free 
radicals, activation of Fas/Fas ligand system, regulation of 
Bcl-2 family proteins (Kuo et al., 2005a; b; 2006), increase 
of wild-type p53, rescue of mutant p53 activity and ini-
tiation of the mitochondrial apoptosis pathway (Garbett 
and Graves., 2004; Kuo et al., 2005a; b; 2006). Ellipticine 
also activates the p53 pathway in glioblastoma cells; its 
impact on these cancer cells depends on the p53 status. In 
a U87MG glioblastoma cell line expressing p53wt, ellipti-
cine provoked an early G0/G1 cell cycle arrest, whereas in 
a U373 cell line expressing p53mt it caused arrest in S and 
G2/M phase (Martínková et al., 2010). 
Ellipticine and 9-hydroxyellipticine also cause selec-
tive inhibition of p53 protein phosphorylation in several 
Introduction
Ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole, 
Figure 1), an alkaloid isolated from Apocyanaceae plants, 
exhibits significant antitumor and anti-HIV activities 
(for a summary see Stiborová et al., 2001). The main 
reason for the interest in ellipticine and its derivatives for 
clinical purposes is their high efficiency against several 
types of cancer, their rather limited toxic side effects, and 
their complete lack of hematological toxicity (Auclair, 
1987). Nevertheless, ellipticine is a potent mutagen. 
Most ellipticine derivatives are mutagenic to Salmonella 
typhimurium A m e s  t e s t e r  s t r a i n s ,  b a c t e r i o p h a g e  T 4 ,  
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human cancer cell lines (Ohashi et al., 1995; Sugikawa et 
al., 1999) and this correlates with their cytotoxic activity. 
However, the precise molecular mechanism responsible for 
these effects has not been explained yet. Chemotherapy-
induced cell cycle arrest was shown to result from DNA 
damage caused by a variety of chemotherapeutics. In the 
case of ellipticine, it has been suggested that the prevalent 
DNA-mediated mechanisms of its antitumor, mutagenic 
and cytotoxic activities are (i) intercalation into DNA and 
(ii) inhibition of DNA topoisomerase II activity (Auclair, 
1987; Garbett & Graves, 2004; Stiborová et al., 2006; 2011). 
We have demonstrated that ellipticine also forms cova-
lent adducts in DNA after being enzymatically activated 
with cytochromes P450 (CYP) such as CYP3A4 (Figure  1 
and 2A) or peroxidases such as LPO (Figure 2B), MPO 
(Figure 2C), COX-1 (Figure 2D) and COX-2 (Figure 2E) 
(Stiborová et al., 2001; 2003a; b; 2004; 2006; 2007a; b; 
Poljaková et al., 2006; Moserová et al., 2008), suggesting 
a third possible mechanism of action. Two major DNA 
adducts generated from 13-hydroxyellipticine (Figure 2F) 
and 12-hydroxyellipticine (Figure 2G) or N2-oxide of 
ellipticine (Figure 2H), which rearranges to 12-hydroxyel-
lipticine by a Polonowski rearrangement (Stiborová et al., 
2004), during the ellipticine CYP- and peroxidase-medi-
ated metabolism are formed in vitro and in vivo in mice 
(Figure 2I) and rats (Figure 2J) treated with this anticancer 
 
 
N
N
H
N
N
N
N
H
O
N
N
H
N
N
CH2OH H
N
N
CH2OH
H
N
N
CH2
+
H
N
N
H
CYP3A4
CYP1A
CYP3A4
CYP2D6
peroxidase
ellipticine
ellipticine-N2-oxide
Polonowski
rearrangement
12-hydroxyellipticine
13-hydroxyellipticine
peroxidase
N
N
. +
N
N
CH2
+ H
peroxidase
- H
+
H
+
+
ellipticine dimer
CYP3A4
CYP2C9
ellipticine methylene-imine
ellipticine-13-ylium
ellipticine-12-ylium
N
N
CH2 NH N
N H
N
N
O
H
DNA
dG adduct 1
NH N
N H
N
N
O
DNA
N
N
CH2
H
dG adduct 2
Figure 1. Scheme of the metabolism of ellipticine by peroxidases and human CYPs showing the characterized metabolites and those pro-
posed to form DNA adducts. The compounds shown in brackets are hypothetical electrophilic metabolites postulated as ultimate arylating 
species or postulated N²-deoxyguanosine adducts.100
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drug (Stiborová et al., 2001; 2003a; b; 2004; 2006; 2007a; 
b; 2008; Frei et al., 2002; Poljaková et al., 2006). The same 
DNA adducts were also detected in cancer cells in cul-
ture, such as human breast adenocarcinoma MCF-7 cells 
(Figure 2L) (Bořek-Dohalská et al., 2004), leukemia HL-60 
(Figure 2M) and CCRF-CEM cells (Figure 2N) (Poljaková 
et al., 2007), neuroblastoma cells (Figure 2O) (Poljaková et 
al., 2009) and glioblastoma cells (Figure 2P) (Martínková 
et al., 2009) in vitro, and in rat breast adenocarcinoma in 
vivo (Figure 2K) (Stiborová et al., 2011). On the basis of 
these data, ellipticine might be considered a drug, whose 
pharmacological efficiency and/or genotoxic side effects 
are dependent on its activation by CYPs and peroxidases 
in target tissues.
In order to evaluate contributions of DNA adduct 
formation by ellipticine to its toxicity to cancer cells, a 
comparison of cytotoxicity and of DNA adduct forma-
tion by 0.1–10 μM ellipticine in different cancer cell 
lines was performed. The 32P-postlabeling method was 
used to determine DNA adduct formation by ellipticine 
and cytotoxicity of ellipticine was determined with the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium-
bromide (MTT) assay (Cinatl et al., 1997). Human cancer 
cell lines sensitive to ellipticine such as human breast 
adenocarcinoma, leukemia, neuroblastoma and glioblas-
toma cancer cells were utilized for this study.
Material and methods
Chemicals 
Ellipticine was obtained from Sigma (St. Louis, MO, 
USA). All other chemicals used in the experiments were 
of analytical purity or better. 
Cell cultures
The MCF-7 cell line was from the collection of cell lines 
o f  t h e  G e r m a n  C a n c e r  R e s e a r c h  C e n t e r  H e i d e l b e r g ,  
Germany). MCF-7 cells were cultivated in Dulbecco’s 
modified Eagle’s medium (DMEM, Biochrom AG, 
Berlin, Germany), high-glucose type (DMEM with 4.5 g 
D-glucose/l), supplemented with 4 mM L-glutamine, 
25 mM HEPES Sigma, St. Louis, MO, U.S.A.), 5% fetal calf 
serum (Biochrom AG, Berlin, Germany) at 37 °C, 5% CO2 
and 95% atmospheric humidity. 
The U87MG cell line was purchased from ATCC 
(Manassas, VA, USA). Cells were cultured in Eagle’s 
MEM supplemented with 10% heat-inactivated fetal 
bovine serum (FBS), 0.6 mg/mL glutamine, 200 interna-
tional unit (IU)/ml penicillin, 200  IU/ml streptomycin, 
and 0.1 mg/ml gentamicin (PAA Laboratories, Pasching, 
Austria) in humidified 5% CO2 at 37 °C.
The CCRF-CEM, a T lymphoblastoid cell line, was 
kindly provided by J.J. McGuire, Roswell Park Cancer 
Institute, (Buffalo, NY, USA) and HL-60 cells (a promy-
elotic line) were from the collection of cell lines of the 
Department of Pediatric Hematology and Oncology, 
2nd Medical School, Charles University and University 
Hospital Motol (Prague, Czech Republic). HL-60 cells 
were cultivated in Iscove’s modified Dulbecco’s medium 
(IMDM, Biochrom AG, Berlin, Germany), high-glucose 
type, supplemented with 4 mM L-glutamine, 10% fetal 
calf serum (PAA Laboratories, Pasching, Austria), 100 
units (U) per ml of penicillin and 100 μg/ ml streptomycin 
(PAA,Vienna, Austria) and 0.3% (w/v) NaHCO3 at 37 °C, 
5% CO2 and 95% atmospheric humidity. CCRF-CEM 
cells were cultivated in RPMI 1640 medium (Biochrom 
AG,Berlin, Germany) supplemented with 2  mM 
L-glutamine, 10% fetal calf serum (PAA Laboratories, 
Pasching, Austria) and 0.3% (w/v) NaHCO3 at 37 °C, 5% 
CO2 and 95% atmospheric humidity. 
The UKF-NB-3 and UKF-NB-4 neuroblastoma cell 
lines, established from bone marrow metastases of high 
risk neuroblastoma, were a gift of Prof. J. Cinatl, Jr. (J. 
W. Goethe University, Frankfurt, Germany). The cell 
line UKF-NB-4 was established from chemoresistant 
recurrency. IMR-32, high risk neuroblastoma derived cell 
line, was of commercial source (LGC Promochem, Wesel, 
Germany). All three cell lines used were derived from 
high risk neuroblastoma with MYCN amplification, del1p 
and aneuploidy. Cells were grown at 37 °C and 5% CO2 in 
Iscove’s modified Dulbecco’s medium (IMDM) (KlinLab 
Ltd, Prague, Czech Republic), supplemented with 10% 
fetal calf serum, 2 mM L-glutamine, 100 units/ml of peni-
cilline and 100 μg/ml streptomycine (PAA Laboratories, 
Pasching, Austria). 
MTT assay
The cytotoxicity of ellipticine was determined by MTT 
test. For a dose-response curve, solution of ellipticine 
in dimethyl sulfoxide (DMSO ) (1 mM) was dissolved in 
culture medium to final concentrations of 0–10 μM. Cells 
in exponential growth were seeded at 1 × 104 per well 
in a 96-well microplate. After incubation (48 hours) at 
37 °C in 5% CO2 saturated atmosphere the MTT solution 
(2 mg/ml PBS) was added, the microplates were incubated 
for 4 hours and cells lysed in 50% N,N-dimethylformamide 
containing 20% of sodium dodecyl sulfate (SDS), pH 4.5. 
The absorbance at 570 nm was measured for each well by 
multiwell ELISA reader Versamax (Molecular devices, 
CA, USA). The mean absorbance of medium controls was 
subtracted as a background. The viability of control cells 
was taken as 100% and the values of treated cells were 
calculated as a percentage of control. The IC50 values 
were calculated from at least 3 independent experiments 
using linear regression of the dose-log response curves by 
SOFTmaxPro.
Treatment of cancer cell lines with ellipticine for DNA adduct analyses
Cell lines were seeded 24 hr prior to treatment at a den-
sity of 1 × 105 cells/ml in two 75 cm3 culture flasks in a 
total volume of 20 ml of IMDM. Ellipticine was dissolved 
in 20  μl of DMSO, the final concentration was 0, 0.1, 
1, 5 or 10 μM. After 48 h the cells were harvested after 
trypsinizing by centrifugation at 2 000 × g for 3 min and 
two washing steps with 5 ml of PBS yielded a cell pellet, 
which was stored at –20 °C until DNA isolation. DNA was 
isolated and labeled as described in the next section. 101
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DNA isolation and 32P-postlabeling of DNA adducts
DNA from cells was isolated by the phenol-chloroform 
extraction as described (Frei et al., 2002; Borek-Dohalská 
et al., 2004; Poljaková et al., 2007; 2009). 32P-postlabeling 
analyses were performed using nuclease P1 enrichment as 
described previously (Stiborová et al., 2001) From experi-
ments performed earlier, calf thymus DNA incubated with 
ellipticine activated with CYP3A4 (Stiborová et al., 2004), 
LPO, MPO, COX-1 and -2 (Stiborová et al., 2007a), with 
13-hydroxyellipticine, 12-hydroxyellipticine and N2-oxide 
of ellipticine (Stiborová et al., 2004; 2007a) and liver DNA 
of rats (Stiborová et al., 2007b) or mice (Stiborová et al., 
2008) treated with ellipticine were labeled with 32P to 
compare adduct spot patterns. 
HPLC analysis of 32P-labeled DNA adducts
HPLC analysis was performed essentially as described 
previously (Stiborová et al., 2003a; b; 2004). Individual 
spots detected by 32P-postlabeling were excised from the 
thin layer and extracted (Stiborová et al., 2003a; b; 2004). 
Cut-outs were extracted with two 800  μl portions of 6 
M ammonium hydroxide/isopropanol (1:1) for 40 min. 
The eluent was evaporated in a Speed-Vac centrifuge. 
The dried extracts were dissolved in 100 μl of methanol/
phosphate buffer (pH 3.5) 1:1 (v/v). Aliquots (50 μl) were 
analyzed on a phenyl-modified reversed-phase column 
(250 mm × 4.6 mm, 5 μm Zorbax Phenyl; Säulentechnik 
Knauer, Berlin, Germany) with a linear gradient of metha-
nol (from 40 to 80% in 45 min) in aqueous 0.5 M sodium 
phosphate and 0.5 M phosphoric acid (pH 3.5) at a flow 
rate of 0.9 ml/min. Radioactivity eluting from the column 
was measured by monitoring Cerenkov radiation with a 
Berthold LB 506 C-I flow-through radioactivity monitor 
(500 μl cell, dwell time 6 s).
Results 
Cytotoxicity of ellipticine to human breast adenocarcinoma MCF-7, 
leukemia HL-60 and CCRF-CEM cells, neuroblastoma IMR-32, 
UKF-NB-3 and UKF-NB-4 cells, and glioblastoma U87MG cells 
To determine the cytotoxicity of ellipticine to human 
breast adenocarcinoma MCF-7, leukemia HL-60 and 
CCRF-CEM cells, neuroblastoma IMR-32, UKF-NB-3 
and UKF-NB-4 cells and glioblastoma UKF87MG cells, 
t h e y  w e r e  t r e a t e d  w i t h  i n c r e a s i n g  c o n c e n t r a t i o n s  o f  
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Figure 2. Autoradiographic profi  les of ellipticine-derived DNA adducts analyzed with the 32P-postlabeling assay. Adduct profi  les obtained 
from calf thymus DNA reacted with ellipticine (100 μM) and CYP3A4 (A), bovine LPO (B), human MPO (C), ovine COX-1 (D), human COX-2 (E), 
from calf thymus DNA reacted with 13-hydroxyellipticine (F), 12-hydroxyellipticine (G), ellipticine N2-oxide (H), from liver DNA of C57BL/6 
mice treated i.p. with 10 mg ellipticine per kilogram body weight (I), from liver DNA of Wistar rats treated i.p. with 40 mg ellipticine per 
kilogram body weight (J), from DNA of breast adenocarcinoma of Wistar rats treated i.p. with 4 mg ellipticine per kilogram body weight 
(K), from DNA of breast adenocarcinoma MCF-7 cells (L), leukemia HL-60 (M) and CCRF-CEM cells (N), neuroblastoma UK-NB-4 cells (O) 
and glioblastoma U87MG cells (P) treated with ellipticine. Cancer cells lines were treated with 10 μM ellipticine except of HL-60 cells that 
were treated with 5  μM ellipticine. Adduct spots 1–7 correspond to the ellipticine-derived DNA adducts. Besides adduct 2 formed by 
12-hydroxyellipticine, another strong adduct (spot X in panel G) was generated, which was not found in any other activation systems or 
in vivo. Experimental conditions for panels A–J are described in our previous studies (Stiborová et al., 2004; 2007a) and those for panels 
L–P in Materials and Methods. Experimental conditions for panel K were as follows: female Wistar rats bearing the N-methyl-N-nitrosourea 
induced mammary adenocarcinoma (McCormick et al., 1981) were i.p. treated with 4 mg ellipticine per kilogram body weight. Ellipticine 
was administered dissolved in 1% acetic acid at a concentration of 2.5 mg/ml. One day after ellipticine treatment, DNA from tumor and 
normal breast tissues (McCormick et al., 1981) was isolated and analyzed for formation of DNA adducts using the nuclease P1 version of 
the 32P-postlabeling assay as described (Stiborová et al., 2001). All experiments with animal models were conducted in accordance with 
the Regulations for the Care and Use of Laboratory Animals (311/1997, Ministry of Agriculture, Czech Republic), which is in compliance 
with the Declaration of Helsinki.102
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ellipticine and viable cells detected with MTT assay. As 
shown in Table 1, all cell lines were sensitive to ellipticine. 
Ellipticine inhibited the growth of all cell lines tested in 
this study in a dose-dependent manner. The IC50 values 
for ellipticine calculated from the dose-log response 
curves are shown in Table 1. Neuroblastoma IMR-32 cells, 
followed by neuroblastoma UKF-NB-4 and UKF-NB-3 
and leukemia HL-60 cells, were the cells most sensitive 
to ellipticine, with IC50 values lower than 1 μM (see IC50 
values shown in Table 1). When sensitivity of additional 
cells to ellipticine was compared, cytotoxicity of this 
agent to human breast adenocarcinoma MCF-7 cells and 
a glioblastoma U87MG cell line was found to be compa-
rable (the IC50 values were around 1 μM), while leukemia 
CCRF-CEM cells were less sensitive. The IC50 value for 
ellipticine was almost 4-times higher in these leukemia 
cells than in MCF-7 and U87MG cells (Table 1).
Determination of DNA adduct formation by ellipticine in 
human breast adenocarcinoma MCF-7, leukemia HL-60 
and CCRF-CEM cells, neuroblastoma IMR-32, UKF-NB-3 
and UKF-NB-4 cells, and glioblastoma U87MG cells 
The cell lines shown to be sensitive to ellipticine (Table 1) 
were treated with increasing concentrations of ellipticine 
(0.1–10 μM) for 48 h and DNA was isolated from these 
cells. Using the nuclease P1 version of 32P-postlabeling 
assay, which was found to be suitable to detect and 
quantify DNA adducts formed by ellipticine (Stiborová et 
al., 2001; 2003a; b; 2004; 2007a; b, 2008; 2011), ellipticine-
derived adducts were detected in the DNA of these cells 
(Figure 2L-P, Table 2). Two major ellipticine-DNA adducts 
(spots 1 and 2 in Figure 2) were formed in all cells (Table 2). 
No adducts were detected in DNA of control cells treated 
with solvent only. 
Chromatographic properties of the two major adduct 
spots on PEI-cellulose TLC plates (spots 1 and 2) were 
similar to those of ellipticine-derived DNA adducts found 
previously after in vitro incubation of calf thymus DNA 
with ellipticine and isolated CYPs (Stiborová et al., 2001; 
2003b; 2004), or peroxidases (Stiborová et al., 2007a) or 
in vivo (Figure 2D), in several organs of rats (Stiborová 
et al., 2003a; 2007b) and mice (Stiborová et al., 2008) 
exposed to this agent. Both these adducts were found to 
be generated from 13-hydroxy- and 12-hydroxyellipticine 
(Figure 2E,F), as confirmed by cochromatographic analy-
sis using TLC and HPLC (data not shown). Both adducts 
w e r e  i d e n t i f i e d  a s  d e o x y g u a n o s i n e  a d d u c t s  i n  D N A  
(Stiborová et al., 2003b; Moserová et al., 2008)). Besides 
these adducts, additional two minor adducts (spots 6 
and 7 in Figure 5C,D) were detected in DNA of MCF-7 
(spot 6) and UKF-NB-4 (spots 6 and 7) cells treated with 
10 μM ellipticine (Table 2, Figure 2). Both these minor 
adducts are known to be generated in vitro mainly by 
peroxidase-catalyzed oxidation (Poljaková et al., 2006; 
Stiborová et al., 2007a). The low levels of these adducts 
prevented HPLC co-chromatographic analysis or their 
further characterization. 
Ellipticine-DNA adduct levels were dose dependent 
in all cells with an overproportional increase between 
1 μM and 10 μM (or 5 μM) ellipticine in MCF-7, HL-60, 
IMR-32, UKF-NB-3, UKF-NB-4 and U87MG cells, but 
not in CCRF-CEM cells (Table 2). The highest levels were 
formed in leukemia HL-60 cells (Table 2).
Discussion
The results of this study show a comparison of ellip-
ticine cytotoxicity to several human cancer cell lines 
(breast adenocarcinoma MCF-7, leukemia HL-60 and 
CCRF-CEM cells, neuroblastoma IMR-32, UKF-NB-3, 
UKF-NB-4 lines and glioblastoma U87MG cells). In addi-
tion, the mechanism of ellipticine cytotoxicity to these 
cells was evaluated. The mode of antitumor, cytotoxic and 
mutagenic action of ellipticine is considered to be based 
mainly on DNA damage, such as intercalation into DNA, 
inhibition of topoisomerase II, and formation of covalent 
DNA adducts mediated by CYPs and peroxidases (Auclair, 
1987, Stiborová et al., 2001; 2006; 2011; Garbett & Graves, 
2004). Intercalation of ellipticine into DNA and inhibition 
of topoisomerase II occur in all cell types irrespective of 
their metabolic capacity, because of the general chemi-
cal properties of this drug and its affinity to DNA and 
topoisomerase II protein (Auclair, 1987). However, the 
formation of ellipticine-DNA adducts, which is dependent 
on ellipticine activation by CYPs and peroxidases, has not 
yet been proven as a general mechanism. we found this 
ellipticine action unambiguously in vitro, using several 
CYP and peroxidase enzymes for ellipticine activation 
(Stiborová et al., 2001; 2003a; b; 2004; 2007a) and in vivo 
in rats and mice (Stiborová et al., 2003a; 2007b; 2008). In 
our former studies (Bořek-Dohalská et al., 2004; Poljaková 
et al., 2007; 2009; Martínková et al., 2009) and in the 
present work, ellipticine-DNA adducts were detected also 
in several human cancer cell lines. Here we evaluated a 
contribution of this mechanism to ellipticine toxicity to 
these cancer cells. 
Toxic effects of ellipticine to leukemia HL-60 and 
CCRF-CEM cells (expressed as IC50 values) correspond 
to levels of ellipticine-DNA adducts formed in these cells. 
This finding indicates that covalent modification of DNA 
Table 1. Cytotoxicity of ellipticine to human cancer cell lines.
Cells IC50 (μM)
Breast adenocarcinoma MCF-7 1.25±0.13
Leukemia HL-60 0.67±0.06
Leukemia CCRF-CEM 4.70±0.48
Neuroblastoma IMR-32 0.27±0.02
Neuroblastoma UKF-NB-3 0.44±0.03
Neuroblastoma UKF-NB-4 0.49±0.04
Glioblastoma U87MG 1.48±0.62
IC50 values were calculated from the linear regression of the dose-log 
response curves. Values are mean ± S.D. of at least 3 experiments. 103
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by ellipticine plays an important role in cytotoxicity 
of ellipticine to these leukemia cells. Even though the 
IC50 values for ellipticine in MCF-7 and U87MG cells 
essentially correspond to levels of DNA adducts formed 
by ellipticine, we cannot account these data as valuable 
because these cell lines are cells of different cancer types. 
In the case of two of neuroblastoma cell lines tested, IMR-
32 and UKF-NB-4, toxic effects of ellipticine to these 
cells also correspond to levels of ellipticine-DNA adducts 
formed in these cells. The cytotoxic activity of ellipticine 
to IMR-32 and UKF-NB-4 neuroblastoma cell lines was 
also previously found to be a consequence of the formation 
of ellipticine-DNA adducts (Poljaková et al., 2009). In 
addition, the role of ellipticine-DNA adduct formation in 
cytotoxicity of this drug to neuroblastoma cells was fur-
ther supported by the finding that a decrease in the levels 
of these adducts in IMR-32 and UKF-NB-4 cells under 
hypoxic conditions correlated with a decrease in toxic-
ity of ellipticine under these conditions (Poljaková et al., 
2009). This is, however, not the case of the UKF-NB-3 cell 
line; lower levels of DNA adducts were found in these cells 
than in UKF-NB-4 cells, although both neuroblastoma 
cells exhibited similar sensitivity to ellipticine. All these 
findings suggest that DNA adduct formation by ellipticine 
Table 2. DNA adduct formation by ellipticine in human cancer cell lines.
Cells
Levels of DNA adducts (RAL x 10-7)a 
Adduct 1 Adduct 2 Adduct 6 Adduct 7 Total
MCF-7 
+ 1.0 μM ellipticine 0.12±0.01 0.20±0.02 n.d. n.d. 0.32±0.03
+ 5 μM ellipticine 1.90±0.20 2.63±0.30 0.17±0.02 n.d. 4.70±0.50
+ 10 μM ellipticine 3.72±0.40 4.77±0.50 0.81±0.07 n.d. 9.30±0.92
HL-60
+ 0.1 μM ellipticine 0.41±0.04 0.24±0.01 n.d. n.d. 0.65±0.07
+ 1.0 μM ellipticine 4.30±0.42 3.20±0.34 n.d. n.d. 7.50±0.73
+ 5 μM ellipticine 46.32±4.30 21.18±2.30 n.d. n.d. 67.50±6.23
CCRF-CEM
+ 0.1 μM ellipticine 0.02±0.01 0.01±0.01 n.d. n.d. 0.03±0.01
+ 1.0 μM ellipticine 1.12±0.01 1.08±0.02 n.d. n.d. 2.20±0.22
+ 5 μM ellipticine 3.60±0.30 3.20±0.40 n.d. n.d. 6.80±0.65
+ 10 μM ellipticine 9.40±0.95 8.40±0.79 n.d. n.d. 17.80±1.62
IMR-32
+ 0.1 μM ellipticine 0.10±0.01 0.13±0.01 n.d. n.d. 0.23±0.02 
+ 1.0 μM ellipticine 0.26±0.02 0.31±0.03 n.d. n.d. 0.57±0.05
+ 10 μM ellipticine 13.15±1.30 13.13±1.30 n.d. n.d. 26.28±2.60
UKF-NB-3 
+ 1.0 μM ellipticine 0.12±0.01 0.23±0.02 n.d. n.d. 0.35± 0.04
+ 10 μM ellipticine 3.26±0.32 2.64±0.40 n.d. n.d. 5.90±0.68
UKF-NB-4
+ 0.1 μM ellipticine 0.04±0.01 0.01±0.01 n.d. n.d. 0.05±0.01 
+ 1.0 μM ellipticine 0.20±0.02 0.38±0.04 n.d. n.d. 0.58±0.06
+ 10 μM ellipticine 5.40±0.56 6.50±0.81 0.27±0.03 0.37±0.05 12.54±1.51
U87MG
+ 1.0 μM ellipticine 0.11±0.01 0.19±0.02 n.d. n.d. 0.30± 0.04
+ 10 μM ellipticine 1.98±0.15 3.42±0.33 n.d. n.d. 5.40±0.53
Cancer cells were exposed to ellipticine for 48 h. DNA adducts were analyzed by the nuclease P1 version of the 32P-postlabeling assay. aRAL, relative adduct 
labeling; averages and S.D. of three experiments. n.d. - not detected (the detection limit of RAL was 1/1010 nucleotides). 104
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might be the predominant mechanism responsible for 
ellipticine cytotoxicity to most of cancer cell lines tested 
in this work, except UKF-NB-3 neuroblastoma cells. Thus 
the DNA adduct formation by ellipticine is probably not 
the major mechanism responsible for ellipticine cytotox-
icity to UKF-NB-3 neuroblastoma cells. Other mecha-
nisms such as intercalation into DNA (Auclair, 1987; 
Singh et al., 1994) and inhibition of DNA topoisomerase 
II activity (Auclair, 1987; Monnot et al., 1991; Fossé et al., 
1992; Froelich-Ammon et al., 1995) that were found to be 
additional DNA-mediated mechanisms of ellipticine anti-
tumor, mutagenic and cytotoxic activities [for a summary 
see (Stiborová et al., 2001; 2006; 2011)] seem to contribute 
to ellipticine cytotoxicity to these neuroblastoma cells. In 
order to resolve the real contribution of covalent DNA 
adduct formation by ellipticine in these cells, additional 
DNA damage such as intercalation of ellipticine into 
DNA in these and other cancer cells should be assessed. 
Recently , we used square wave voltametry to evaluate 
intercalation of ellipticine into DNA in vitro and covalent 
modification of DNA by ellipticine in a UKF-NB-3 neuro-
blastoma cell line and found participation of both these 
mechanisms in DNA damage caused by this drug in this 
neuroblastoma cell line (Huska et al., 2010a; Huska et al., 
2010b). Nevertheless, further detailed studies have to be 
performed which would examine differences in electro-
chemical signals of DNA with intercalated ellipticine and 
DNA covalently modified by this antitumor agent. 
In our former studies, toxic effects of ellipticine 
to several cancer cells were found to be dependent on 
expression of CYP1A1, 1B1, 3A4 and peroxidases LPO, 
COX and MPO in these cells (Bořek-Dohalská et al., 2004; 
Poljaková et al., 2007; 2009; Martínková et al., 2009). 
Moreover, expression of CYP1A1, 1B1 and 3A4 enzymes 
was found to be induced by treating glioblastoma U87MG, 
adenocarcinoma MCF-7 and neuroblastoma UKF-NB-4 
cells with ellipticine (Martínková et al., 2009; Stiborová 
et al., unpublished results). Likewise, CYP1A1 was found 
to be induced by ellipticine in rats in vivo (Aimová et al., 
2007). Hence, the sensitivity of individual cancer cells to 
ellipticine caused by covalent modification of DNA might 
be dependent on the capability of ellipticine to induce the 
CYP enzymes oxidizing ellipticine to 13-hydroxy- and 
12-hydroxyellipticine, the metabolites generating DNA 
adducts. This suggestion, however, needs to be confirmed 
by further investigations including in vivo studies. 
This feature is one of the aims of investigations in our 
laboratory. 
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